Beam Therapeutics(US:BEAM) Globenewswire·2026-02-24 12:00Core Insights - Beam Therapeutics has secured a $500 million senior secured credit facility with Sixth Street to support the launch of ristoglogene autogetemcel (risto-cel) for sickle cell disease (SCD) [1][2] - The financing includes $100 million funded at close, with up to $300 million available upon achieving specific milestones, and an additional $100 million available at Beam's option during the seven-year term [1][2] Group 1: Financing Details - The credit facility matures in early 2033 and has an interest rate of approximately 10% based on current forward projections for SOFR [2] - There are no scheduled amortization payments, with all principal amounts due at maturity [2] - Beam expects to draw a minimum of $200 million under the facility and will make mandatory prepayments from certain extraordinary receipts [2] Group 2: Strategic Importance - The financing provides Beam with significant flexibility and non-dilutive capital to support the anticipated commercial launch and revenue generation for risto-cel, which is viewed as a potential best-in-class treatment for SCD [2] - This facility secures a high-value franchise for Beam and enhances its ability to invest in the growth of its pipeline and long-term vision for precision genetic medicines [2] Group 3: Company Overview - Beam Therapeutics is focused on precision genetic medicines, utilizing a proprietary base editing technology that allows for precise genetic modifications without double-stranded breaks in DNA [4] - The company aims to provide life-long cures for patients suffering from serious diseases through its diversified portfolio of base editing programs [4] Group 4: Partner Overview - Sixth Street is a global investment firm with over $125 billion in assets under management, focusing on flexible capital solutions in the healthcare sector [5][6] - The firm is committed to long-term partnerships with companies that can address healthcare challenges and improve patient outcomes [5]